MannKind (MNKD) Stock Price
MannKind Price
MannKind (MNKD) Stock | ISIN US56400P7069 | WKN A2DMZL. The current MannKind stock price is 3.39 USD (2026). Revenue is 473.92 M USD. Net income is 16.73 M USD. The P/E ratio is 63.64. Market capitalization is 1.06 B USD. MannKind operates in the Health sector.
MannKind stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MannKind over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MannKind stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MannKind's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MannKind Price |
|---|
MannKind Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MannKind generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MannKind retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MannKind's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MannKind has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MannKind's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MannKind stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind business model & stock analysis
MannKind SWOT Analysis
Strengths
MannKind Corp operates in the biopharmaceutical industry, specializing in the development and commercialization of novel therapeutic products.
The company possesses advanced scientific and technological expertise, allowing them to innovate and create unique pharmaceutical products.
MannKind has a successful track record in drug development, with a portfolio of approved products that cater to critical medical needs.
Weaknesses
MannKind Corp heavily relies on partnerships for its commercialization and distribution activities, which can limit their control over the entire supply chain.
The company faces financial challenges due to high research and development costs, impacting their ability to generate consistent profits.
MannKind may have limited resources for marketing and promotion compared to larger pharmaceutical competitors.
Opportunities
The increasing demand for innovative pharmaceutical products presents MannKind Corp with opportunities to expand its product portfolio and capture a larger market share.
The company can explore international markets and partnerships to further grow its global presence and increase revenues.
Technological advancements and medical breakthroughs provide MannKind with the chance to develop and introduce new drugs to address unmet medical needs.
Threats
MannKind Corp operates in a highly competitive industry, facing intense competition from well-established pharmaceutical companies.
Regulatory changes and requirements pose a threat to the company's ability to obtain necessary approvals and licenses for its products.
The potential emergence of substitute products or alternative therapies may impact the demand for MannKind's offerings.
MannKind Segments
MannKind Revenue by Segment (1/7)
Max
Details
MannKind Revenue by Segment (2/7)
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind Revenue by Segment (3/7)
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind Revenue by Segment (4/7)
Max
Details
MannKind Revenue by Segment (5/7)
Max
Details
MannKind Revenue by Segment (6/7)
Max
Details
MannKind Revenue by Segment (7/7)
Max
Details
MannKind Eulerpool Fair Value
MannKind historical P/E ratio, EBIT multiple, and P/S ratio
MannKind annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MannKind shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
MannKind Earnings Estimates
MannKind Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/13/2026 | -0USD | 108.69 MUSD | 2026 Q1 |
| 5/6/2026 | -0.01USD | 109.49 MUSD | 2026 Q1 |
| 3/3/2026 | 0.01USD | 99.56 MUSD | 2025 Q4 |
| 2/26/2026 | 0.01USD | 99.56 MUSD | 2025 Q4 |
| 2/24/2026 | 0.01USD | 99.56 MUSD | 2025 Q4 |
| 5/7/2024 | -0.01USD | 61.92 MUSD | 2024 Q1 |
| 2/21/2024 | 0.01USD | 56.8 MUSD | 2023 Q4 |
| 2/22/2023 | -0.06USD | 36.04 MUSD | 2022 Q4 |
| 11/8/2022 | -0.09USD | 25.85 MUSD | 2022 Q3 |
| 8/9/2022 | -0.1USD | 15.86 MUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the MannKind stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
MannKind shareholder structure
| % | Name |
|---|---|
7.57576% | |
5.67235% | |
4.65543% | |
2.3802% | |
2.34761% | |
1.69552% | |
1.62461% | |
1.41492% | |
1.41466% | |
1.34506% |
MannKind Executives and Management Board
Dr. Michael Castagna
(48)Chief Executive Officer, Director · since 2016
Mr. Christopher Prentiss
(49)Chief Financial Officer
Dr. David Thomson
(58)Executive Vice President, General Counsel, Secretary
Dr. Stuart Tross
(58)Executive Vice President, Chief People and Workplace Officer
Mr. Steven Binder
(61)Director · since 2017
MannKind Supply Chain
Frequently asked questions about MannKind
MannKind Corp is a pharmaceutical company with a rich history and background. Established in 1991, MannKind Corp primarily focuses on the discovery, development, and commercialization of therapeutic products for patients with various medical conditions. With its headquarters in Westlake Village, California, MannKind Corp has made notable contributions to the pharmaceutical industry. It is best known for its groundbreaking development of Afrezza®, an inhaled insulin used in the treatment of diabetes. MannKind Corp remains committed to advancing medical innovation and improving the lives of patients worldwide through its cutting-edge research and development efforts.
MannKind stock
MannKind Peer Group
MannKind Ticker
MannKind FIGI
All fundamentals and in-depth analysis of MannKind
Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.